HIGH DOSE SEQUENTIALCHEMOTHERAPY WITH RITUXIMAB AND ASCT AS FIRST LINE THERAPY IN ADULT MCL PATIENTS: CLINICAL AND MOLECULARRESPONSE OF THE MCL0208 TRIAL, A FIL STUDY

被引:0
|
作者
Cortelazzo, S. [1 ]
Martelli, M. [2 ]
Ladetto, M. [3 ]
Ferrero, S. [4 ]
Ciccone, G. [5 ]
Evangelista, A. [5 ]
Mian, M. [6 ]
Di Rocco, A. [2 ]
Chiappella, A. [7 ]
Rossi, G. [8 ]
Re, A. [9 ]
Zinzani, P. L. [10 ]
Balzarotti, M. [11 ]
Cavallo, F. [4 ]
Rusconi, C. [12 ]
Gotti, M. [13 ]
Arcaini, L. [13 ]
Gobbi, M. [14 ]
Gomes, M. [15 ]
Molinari, A. [16 ]
Liberati, A. M. [17 ]
Michieli, M. [18 ]
Latte, G. [19 ,20 ]
Cabras, M. G. [21 ]
Novero, D. [22 ]
Paulli, M. [23 ]
Zamo, A. [24 ,25 ]
Chilosi, M. [24 ,25 ]
Federico, M. [26 ]
Vitolo, U. [7 ]
机构
[1] Ist Clin Humanitas Gavazzeni, Unita Oncol Med & Ematol, Hematol, Bergamo, Italy
[2] Univ Roma La Sapienza, Dip Biotecnol Cellulari & Ematol, Hematol, I-00185 Rome, Italy
[3] AO SS Antonio & Biagio, SC Ematol, Hermatol, Alessandria, Italy
[4] SCDU Ematol Univ, AO Citta Salute & Sci, Hematol, Turin, Italy
[5] AO Citta Salute & Sci, CPO Piemonte Ctr Riferimento Epidemiol & Prevenz, Epidemiol, Turin, Italy
[6] Med Univ Innsbruck, Dept Hematol & Oncol, Hematol, A-6020 Innsbruck, Austria
[7] AO Citta Salute & Sci, SC Ematol, Hematol, Turin, Italy
[8] Spedali Civil Brescia, SC Ematol, Hematol, I-25125 Brescia, Italy
[9] Spedali Civil Brescia, SC Ematol, Hermatol, I-25125 Brescia, Italy
[10] St Orsola Marcello Malpighi Hosp, Ist Ematol & Oncol Med Seragnoli, Hematol, Bologna, Italy
[11] Ist Clin Human, Hematol Oncol Med & Ematol, Rozzano, Italy
[12] Osped Maggiore Niguarda, Div Ematol, Hematol, Milan, Italy
[13] Fdn IRCCS Policlin San Matteo, Dipartimento Ematol Oncol, Hematol, Pavia, Italy
[14] IRCCS AOU San Martino IST, Clin Ematol, Hematol, Genoa, Italy
[15] Inst Portugues Oncol Francisco Gentil, Dept Hematol, Hematol, Lisbon, Portugal
[16] Osped Infermi, UO Ematol, Hematol, Rimini, Italy
[17] Osped Santa Maria, Struttura Complessa Oncoematol, Hematol, Terni, Italy
[18] Med A Ctr Riferimento Oncol, Oncol, Aviano, Italy
[19] UOC Ematol, Hematol, Nuoro, Italy
[20] CTMO Presidio Osped S Francesco, Nuoro, Italy
[21] Osped Businco, Div Ematol, Hematol, Cagliari, Italy
[22] AO Citta Salute & Sci, Anat Patol, Pathol, Turin, Italy
[23] Dipartimento Sci Pediat & Patol Umana, Sez Anat Patol, Pathol, Pavia, Italy
[24] Univ Verona, Dipartimento Patol & Diagnost, Pathol, I-37100 Verona, Italy
[25] AOUI Verona, Verona, Italy
[26] Univ Modena & Reggio Emilia, Policlin, COM Ctr Oncol Modenese, Oncol,Dipartimento Oncol & Ematol, Modena, Italy
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
S106
引用
收藏
页码:3 / 4
页数:2
相关论文
共 50 条
  • [11] Comprehensive Minimal Residual Disease (MRD) Analysis of the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial for Younger Patients with Mantle Cell Lymphoma: A Kinetic Model Ensures a More Refined Risk Stratification
    Ferrero, Simone
    Daniela, Barbero
    Lo Schirico, Mariella
    Evangelista, Andrea
    Cifaratti, Annalisa
    Drandi, Daniela
    Genuardi, Elisa
    Grimaldi, Daniele
    Monitillo, Luigia
    Zaccaria, Gian Maria
    Stefani, Pietro Maria
    Benedetti, Fabio
    Casaroli, Ivana
    Zanni, Manuela
    Castellino, Claudia
    Pavone, Vincenzo
    Petrini, Mario
    Re, Francesca
    Hohaus, Stefan
    Musuraca, Gerardo
    Cascavilla, Nicola
    Congiu, Angela Giovanna
    Liberati, Anna Marina
    Ciccone, Giovannino
    Vitolo, Umberto
    Cortelazzo, Sergio
    Ladetto, Marco
    BLOOD, 2018, 132
  • [12] FOCUS ON PATIENTS WITH TP53 DISRUPTION IN THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 TRIAL: UNIFORM POOR OUTCOME, REGARDLESS OF BASELINE PREDICTORS, MRD STATUS AND LENALIDOMIDE MAINTENANCE
    Alessandria, B.
    Ferrero, S.
    Zaccaria, G. M.
    Grimaldi, D.
    Moia, R.
    Genuardi, E.
    Ghislieri, M.
    Favini, C.
    Di Rocco, A.
    Re, A.
    Stefoni, V.
    Cavallo, F.
    Boccomini, C.
    Balzarotti, M.
    Zilioli, V. Ruggero
    Gomes da Silva, M.
    Arcaini, L.
    Molinari, A. Lia
    Ballerini, F.
    Ferreri, A.
    Evangelista, A.
    Cortelazzo, S.
    Bertoni, F.
    Rossi, D.
    Gaidano, G.
    Ladetto, M.
    HAEMATOLOGICA, 2020, 105 : S52 - S53
  • [13] Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)
    Ferrero, Simone
    Grimaldi, Daniele
    Arrigoni, Elena
    Zaccaria, Gian Maria
    Alessandria, Beatrice
    Genuardi, Elisa
    De Luca, Gabriele
    Ghislieri, Marco
    Di Rocco, Alice
    Re, Alessandro
    Stefoni, Vittorio
    Cavallo, Federica
    Boccomini, Carola
    Balzarotti, Monica
    Zilioli, Vittorio Ruggero
    Maria, Gomes Da Silva
    Arcaini, Luca
    Molinari, Anna Lia
    Ballerini, Filippo
    Ferreri, Andres Jm
    Puccini, Benedetta
    Palumbo, Giuseppe A.
    Galimberti, Sara
    Cortelazzo, Sergio
    Di Paolo, Antonello
    Ladetto, Marco
    BLOOD, 2020, 136
  • [14] Identification of DNA Copy Number Variations Associated with the Clinical Outcome in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in the Prospective from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL)
    Rinaldi, Andrea
    Ferrero, Simone
    Kwee, Ivo
    Rossi, Davide
    Bruscaggin, Alessio
    Spina, Valeria
    Diop, Fary
    Ballerini, Filippo
    Gherlinzoni, Filippo
    Benedetti, Fabio
    Mian, Michael
    Stelitano, Caterina
    Doni, Elisa
    Salvi, Alessandra Flavia
    Cortelazzo, Sergio
    Ladetto, Marco
    Gaidano, Gianluca
    Bertoni, Francesco
    BLOOD, 2016, 128 (22)
  • [15] A Molecular Model for the Prediction of Progression Free Survival in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation: Results from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL)
    Rossi, Davide
    Ferrero, Simone
    Bruscaggin, Alessio
    Ghione, Paola
    Di Rocco, Alice
    Spina, Valeria
    Stefoni, Vittorio
    Ciccone, Giovannino
    Barbero, Daniela
    Monitillo, Luigia
    Da Silva, Maria Comes
    Santoro, Armando
    Molinari, Annalia
    Ferreri, Andres J. M.
    Cortelazzo, Sergio
    Ladetto, Marco
    Gaidano, Gianluca
    BLOOD, 2015, 126 (23)
  • [16] Immunoglobulin recovery following high dose therapy,and post-ASCT rituximab for relapsed follicular Lymphoma(FL) and newly diagnosed mantle cell lymphoma (MCL) compared to standard dose chemotherapy +/- Rituximab®.
    Buckstein, RJ
    Mangel, J
    Imrie, KR
    Spaner, D
    Boudreau, A
    Crump, M
    Pao, J
    Foden, C
    Berinstein, N
    BLOOD, 2002, 100 (11) : 480B - 480B
  • [17] Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients
    Mato, Anthony R.
    Protomastro, Ewelina A.
    Zielonka, Tania
    Feldman, Tatyana
    Rowley, Scott D.
    Donato, Michele L.
    Pecora, Andrew L.
    Bhattacharyya, Pritish K.
    Timberg, Mary
    Stives, Susan
    Gadaleta, Gabriella
    Bejot, Coleen
    Goy, Andre
    BLOOD, 2012, 120 (21)
  • [18] The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
    Holte, Harald
    Beiske, Klaus
    Boyle, Merrill
    Troen, Gunhild
    Blaker, Yngvild N.
    Myklebust, June
    Kvaloy, Sunniva
    Rosenwald, Andreas
    Lingjaerde, Ole C.
    Rimsza, Lisa M.
    Smeland, Erlend B.
    Scott, David W.
    Kolstad, Arne
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (02) : 225 - 234
  • [19] Long-Term Clinical and Molecular Remissions in Patients with Mantle Cell Lymphoma (MCL) Following High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)
    Metzner, Bernd
    Casper, Jochen
    Claus-Henning, Koehne
    Renzelmann, Andrea
    Mueller, Thomas H.
    Petershofen, Eduard K.
    Rosien, Bernd
    Thole, Ruth
    Voss, Andreas
    Dreyling, Martin H.
    Hoster, Eva
    Klapper, Wolfram
    Pott, Christiane
    BLOOD, 2019, 134
  • [20] Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
    Flinn, Ian W.
    van der Jagt, Richard
    Kahl, Brad S.
    Wood, Peter
    Hawkins, Tim E.
    MacDonald, David
    Hertzberg, Mark
    Kwan, Yiu-Lam
    Simpson, David
    Craig, Michael
    Kolibaba, Kathryn
    Issa, Samar
    Clementi, Regina
    Hallman, Doreen M.
    Munteanu, Mihaela
    Chen, Ling
    Burke, John M.
    BLOOD, 2014, 123 (19) : 2944 - 2952